| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
D1 dopamine receptor (D1-like dopamine receptor).
|
|---|---|
| ln Vitro |
MLS1082 improves D1R signaling mediated by G proteins and β-Arrestin. [1].
MLS1082 is a positive allosteric modulator of the D1 dopamine receptor that potentiates dopamine-stimulated G-protein-mediated signaling and β-arrestin-mediated signaling with an EC50 of 123 nM. It binds to a different allosteric site than MLS6585. The compound is a pyrimidone-based D1-like dopamine receptor positive allosteric modulator. MLS1082 is used as a chemical tool to study D1 dopamine receptor signaling and allosteric modulation. |
| ln Vivo |
In vivo efficacy data for MLS1082 is limited. The compound is primarily used as an in vitro tool for studying D1 dopamine receptor signaling and allosteric modulation. As a positive allosteric modulator, it has potential applications in studying dopamine receptor function in neurological and psychiatric disorders. Further in vivo studies in animal models of dopamine-related disorders would be needed to assess its therapeutic potential.
|
| Enzyme Assay |
The in vitro receptor binding assay for D1 dopamine receptor allosteric modulation uses membrane preparations from cells expressing recombinant human D1 dopamine receptor. MLS1082 is incubated with the receptor preparation and a radiolabeled D1 receptor ligand (e.g., [3H]SCH23390) at varying concentrations (typically 0.1 nM to 100 µM). Allosteric modulation is assessed by measuring the effect of MLS1082 on dopamine binding affinity or by measuring dopamine-stimulated signaling in the presence of the compound. The EC50 for potentiation of dopamine signaling is calculated from dose-response curves.
|
| Cell Assay |
In vitro cellular assays are performed using cells expressing recombinant human D1 dopamine receptor (e.g., HEK293 cells). Cells are treated with MLS1082 at concentrations ranging from 0.01 to 100 µM in the presence of varying concentrations of dopamine. G-protein-mediated signaling is assessed by measuring cAMP accumulation using a competitive immunoassay (e.g., ELISA or HTRF). β-arrestin recruitment is measured using BRET or ELISA-based assays. The EC50 for potentiation of dopamine-stimulated signaling is calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal model data for MLS1082 is not extensively reported in the literature. As a research tool for studying D1 dopamine receptor signaling, the compound would typically be evaluated in rodent models of dopamine-related disorders such as Parkinson's disease, schizophrenia, or addiction. Standard efficacy studies would involve compound administration (oral or intraperitoneal) followed by assessment of behavioral endpoints, motor function, and dopamine-related signaling markers. Pharmacokinetic studies would assess oral bioavailability, plasma half-life, and brain penetration.
|
| ADME/Pharmacokinetics |
MLS1082 has a molecular weight of approximately 400 g/mol and is a pyrimidone-based compound. It is soluble in DMSO and should be stored as a powder at -20°C. Pharmacokinetic parameters such as oral bioavailability, plasma half-life, and brain penetration are not extensively characterized in publicly available literature. As a research compound, it is typically used in in vitro assays at concentrations ranging from nanomolar to low micromolar.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available for MLS1082. As a research compound, it is not intended for human use and has not undergone formal toxicological evaluation. Standard preclinical safety assessments for dopamine receptor modulators would typically include selectivity profiling against a panel of dopamine receptor subtypes and related GPCRs, hERG channel inhibition for cardiac safety, and CYP450 enzyme inhibition for drug-drug interaction potential. The compound is supplied as a solid and should be stored desiccated at -20°C.
|
| References | |
| Additional Infomation |
MLS1082 is a research-grade D1 dopamine receptor positive allosteric modulator that potentiates dopamine-stimulated G-protein and β-arrestin-mediated signaling. It is not approved for clinical use. The compound binds to a different allosteric site than MLS6585. MLS1082 is a pyrimidone-based compound used as a chemical tool to study D1 dopamine receptor signaling and allosteric modulation. It is supplied as a solid with high purity and should be stored desiccated at -20°C.
|
| Molecular Formula |
C24H23N3O2
|
|---|---|
| Molecular Weight |
385.47
|
| Exact Mass |
385.179
|
| CAS # |
883958-36-9
|
| PubChem CID |
2030130
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
520.1±60.0 °C at 760 mmHg
|
| Flash Point |
268.4±32.9 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.688
|
| LogP |
2.78
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
29
|
| Complexity |
743
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1C2=CC=CC=C2C(=O)C3=C1N=C(N(C3=O)C4=CC=CC=C4)C5CCCCC5
|
| InChi Key |
HZGMAMIIHBRAAR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H23N3O2/c1-26-19-15-9-8-14-18(19)21(28)20-23(26)25-22(16-10-4-2-5-11-16)27(24(20)29)17-12-6-3-7-13-17/h3,6-9,12-16H,2,4-5,10-11H2,1H3
|
| Chemical Name |
2-cyclohexyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5-dione
|
| Synonyms |
MLS1082; MLS 1082; MLS-1082
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5942 mL | 12.9712 mL | 25.9424 mL | |
| 5 mM | 0.5188 mL | 2.5942 mL | 5.1885 mL | |
| 10 mM | 0.2594 mL | 1.2971 mL | 2.5942 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
